搜索
Blueprint Medicines Corp
BPMC添加自选
129.460USD
0.0000.00%
交易中 （美东）报价延迟15分钟
8.36B总市值
亏损市盈率 TTM
关于 Blueprint Medicines Corp 公司
Blueprint Medicines Corporation 是一家全球精准治疗公司，正在过敏/炎症和肿瘤/血液学两个领域发明改变生命的药物。该公司向美国和欧洲的患者提供其获批的药物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，并在全球范围内推进针对系统性肥大细胞增多症 (SM)、肺癌、乳腺癌和其他基因组定义的癌症以及癌症免疫疗法的多个项目。该公司的产品线还包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究项目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外显子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。该公司正在开发一种口服、有效且高选择性的试验性 KIT 抑制剂 Elenestinib (BLU-263)，用于治疗惰性 SM 和其他肥大细胞疾病。
Blueprint Medicines Corp简介
公司代码BPMC
公司名称Blueprint Medicines Corp
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
员工数量649
证券类型Ordinary Share
年结日Apr 30
公司地址45 Sidney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02139
电话16173747580
网址https://www.blueprintmedicines.com/
公司代码BPMC
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Blueprint Medicines Corp公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+0.03%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+0.10%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-0.10%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-0.08%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-0.51%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+0.03%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+0.10%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-0.10%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-0.08%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-0.51%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
常见问题
Blueprint Medicines Corp的前五大股东是谁？
Blueprint Medicines Corp 的前五大股东如下：Ms. Kathryn D (Kate) Haviland
有多少机构持有Blueprint Medicines Corp(BPMC)的股份？
截至2025Q2，共有701家机构持有Blueprint Medicines Corp的股份，合计持有的股份价值约为68.81M，占公司总股份的106.41%。与2025Q1相比，机构持股有所增加，增幅为-3220329.00。
哪个业务部门对Blueprint Medicines Corp的收入贡献最大？
在2025Q2，Product revenue业务部门对Blueprint Medicines Corp的收入贡献最大，创收128.18M，占总收入的100.00%。
